A phase II study of sequential capecitabine plus oxaliplatin (XELOX) followed by docetaxel plus capecitabine (TX) in patients with unresectable gastric adenocarcinoma: The TCOG T3211 trial.

Authors

Ming-Huang Chen

Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

Ming-Huang Chen , June-Seng Lin , Chin-Fu Hsiao , Yan-Shen Shan , Yeu-Chin Chen , Li-Tzong Chen , Tsang-Wu Liu , Chung-Pin Li , Yee Chao

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2014 Gastrointestinal Cancers Symposium

bookmark_border

A multicenter, phase II study of trastuzumab plus capecitabine and oxaliplatin (XELOX) as first-line chemotherapy for HER2-positive advanced gastric cancer: Update results of efficacy and toxicity.

First Author: Jifang Gong

insert_chart_outlined

Poster

2020 Gastrointestinal Cancers Symposium

bookmark_border

A multicenter phase II trial of tumor treating fields plus chemotherapy for first-line treatment of gastric adenocarcinoma.

First Author: Jin Li

insert_chart_outlined

Poster

2020 Gastrointestinal Cancers Symposium

bookmark_border

Quattro-II study: A multicenter randomized phase II study comparing capoxiri plus bevacizumab with FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer as the first-line treatment.

First Author: Akihito Tsuji

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

A randomized, placebo-controlled, phase III trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC).

First Author: Jian-Ming Xu